Published January 31, 2020 | Version v1
Journal article Open

MORPHOLOGICAL AND STRUCTURAL CHANGES IN MYOCARDIUM, LIPID AND CARBOHYDRATE METABOLISM DURING DIFFERENT OUTCOMES OF CHRONIC HEART FAILURE IN PATIENTS WITH ISCHEMIC HEART DISEASE AND DIABETES MELLITUS TYPE II

Authors/Creators

  • 1. Kharkiv Medical Academy of Postgraduate Education
  • 2. National Aerospace University – "Kharkiv Aviation Institute"
  • 3. Kharkiv National Medical University

Description

Diabetes mellitus (DM) type II is an independent risk factor for cardiovascular system injury. To avoid progression of ischemic heart failure (IHF) it is important to find early signs of myocardial injury also as carbohydrate and lipid metabolism alterations.

The objective of the study: to establish features of structural and functional changes in myocardium, carbohydrate and lipid metabolism, in patients with different outcomes of chronic heart failure (CHF), caused by IHD and DM type II.

Material and methods. Examination of 100 patients who have CHF with IHF and DM type II was performed. Patients were divided in two groups, according to outcome: group I (n=66) – patients with favorable outcome, mean age 60.0 [55.8; 63.3] years, group II (n=34) – unfavorable outcome of CHF, mean age 58.0 [55.0; 60.3] years.

We analysed complaints, cardiologycal anamnesis, cardiovascular risk factors, and physical examination data. Transthoracic echocardiography (TTE), carbohydrate and lipid panel were assessed to find out early specific signs of myocardial injury.

Results. We find out statistically significant associations between TTE results, lipid panel and CHF progression in study population.

Conclusions. Comparative analysis showed that degree of CHF in patients with IHD and DM type II that have preserved LV EF is associated with: duration of DM and CHF, arterial hypertension (AH) level and degree of carbohydrate and lipid metabolism disturbances. Early TTE signs of unfavorable outcome are: increase of transmitral deceleration time (Dt), increase of mean PA pressure (PA MP) even in range lower the 20 mmHg.

Files

MORPHOLOGICAL AND STRUCTURAL CHANGES IN MYOCARDIUM, LIPID AND CARBOHYDRATE METABOLISM DURING DIFFERENT OUTCOMES OF CHRONIC HEART FAILURE IN PATIENTS.pdf

Files (377.4 kB)

Additional details

References

  • Severino, P., D'Amato, A., Netti, L., Pucci, M., De Marchis, M., Palmirotta, R. et. al. (2018). Diabetes Mellitus and Ischemic Heart Disease: The Role of Ion Channels. International Journal of Molecular Sciences, 19 (3), 802. doi: https://doi.org/10.3390/ijms19030802
  • IDF Diabetes Atlas (2015). Available at: https://www.idf.org/e-library/epidemiology-research/diabetes-atlas/13-diabetes-atlas-seventh-edition.html
  • Kumar, R., Kerins, D. M., Walther, T. (2015). Cardiovascular safety of anti-diabetic drugs. European Heart Journal – Cardiovascular Pharmacotherapy, 2 (1), 32–43. doi: http://doi.org/10.1093/ehjcvp/pvv035
  • Stratton, I. M., Adler, A. I., Neil, H. A. et. al. (2000). Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ, 321 (7258), 405–412. doi: http://doi.org/10.1136/bmj.321.7258.405
  • Chatterjee, S., Khunti, K., Davies, M. J. (2017). Type 2 diabetes. The Lancet, 389 (10085), 2239–2251. doi: http://doi.org/10.1016/s0140-6736(17)30058-2
  • Bowes, C. D., Lien, L. F., Butler, J. (2019). Clinical aspects of heart failure in individuals with diabetes. Diabetologia, 62 (9), 1529–1538. doi: http://doi.org/10.1007/s00125-019-4958-2
  • Jia, G., Whaley-Connell, A., Sowers, J. R. (2017). Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart disease. Diabetologia, 61 (1), 21–28. doi: http://doi.org/10.1007/s00125-017-4390-4
  • Yahagi, K., Kolodgie, F. D., Lutter, C., Mori, H., Romero, M. E., Finn, A. V., Virmani, R. (2017). Pathology of Human Coronary and Carotid Artery Atherosclerosis and Vascular Calcification in Diabetes Mellitus. Arteriosclerosis, Thrombosis, and Vascular Biology, 37 (2), 191–204. doi: http://doi.org/10.1161/atvbaha.116.306256
  • Saotome, M., Ikoma, T., Hasan, P., Maekawa, Y. (2019). Cardiac Insulin Resistance in Heart Failure: The Role of Mitochondrial Dynamics. International Journal of Molecular Sciences, 20 (14), 3552. doi: http://doi.org/10.3390/ijms20143552
  • Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S. et. al. (2016). 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 37 (27), 2129–2200. doi: http://doi.org/10.1093/eurheartj/ehw128
  • American diabetes association. Standards of Medical Care in Diabetes–2017 (2017). Diabetes Care, 40 (1), 135.
  • Klimov, A. N. (1977). Prichiny i usloviya razvitiya ateroskleroza. Preventivnaya kardiologiya, 260–321.
  • Alfian, S. D., Sukandar, H., Lestari, K., Abdulah, R. (2016). Medication Adherence Contributes to an Improved Quality of Life in Type 2 Diabetes Mellitus Patients: A Cross-Sectional Study. Diabetes Therapy, 7 (4), 755–764. doi: http://doi.org/10.1007/s13300-016-0203-x
  • Savarese, G., Lund, L. H. (2017). Global Public Health Burden of Heart Failure. Cardiac Failure Review, 3 (1), 7–11. doi: http://doi.org/10.15420/cfr.2016:25:2
  • Udell, J. A., Cavender, M. A., Bhatt, D. L., Chatterjee, S., Farkouh, M. E., Scirica, B. M. (2015). Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. The Lancet Diabetes & Endocrinology, 3 (5), 356–366. doi: http://doi.org/10.1016/s2213-8587(15)00044-3
  • Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V. et. al. (2019). 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal, 41 (2), 255–323. doi: http://doi.org/10.1093/eurheartj/ehz486
  • Braunwald, E. (2015). The war against heart failure: the Lancet lecture. The Lancet, 385 (9970), 812–824. doi: http://doi.org/10.1016/s0140-6736(14)61889-4
  • Lam, C. S. (2015). Diabetic cardiomyopathy: An expression of stage B heart failure with preserved ejection fraction. Diabetes and Vascular Disease Research, 12 (4), 234–238. doi: http://doi.org/10.1177/1479164115579006
  • Lehrke, M., Marx, N. (2017). Diabetes Mellitus and Heart Failure. The American Journal of Medicine, 130 (6), S40–S50. doi: http://doi.org/10.1016/j.amjmed.2017.04.010
  • Cleland, J. G. F., Bunting, K. V., Flather, M. D., Altman, D. G., Holmes, J. et. al. (2017). Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. European Heart Journal, 39 (1), 26–35. doi: http://doi.org/10.1093/eurheartj/ehx564
  • Lund, L. H., Claggett, B., Liu, J., Lam, C. S., Jhund, P. S., Rosano, G. M. et. al. (2018). Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. European Journal of Heart Failure, 20 (8), 1230–1239. doi: http://doi.org/10.1002/ejhf.1149
  • January, C. T., Wann, L. S., Alpert, J. S., Calkins, H., Cigarroa, J. E., Cleveland, J. C. et. al. (2014). 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary. Circulation, 130 (23), 2071–2104. doi: http://doi.org/10.1161/cir.0000000000000040